Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
ShunzymeX leverages a proprietary protease to streamline purification
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Under the deal, Quiver will receive an undisclosed advance payment and research support
Subscribe To Our Newsletter & Stay Updated
